Dogwood Therapeutics DWTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.1M+1.1% | $21.87M+0.1% | $21.84M+178% | $7.86M+39.7% | $5.62M+59.3% | ||
| $6.52M+6.8% | $6.1M-38.1% | $9.86M-4.6% | $10.34M+6.4% | $9.72M+11.8% | ||
| $28.61M+2.3% | $27.97M-11.8% | $31.7M+74.2% | $18.2M+18.6% | $15.34M+25.5% | ||
| -$28.61M-2.3% | -$27.97M+11.8% | -$31.7M-74.2% | -$18.2M-18.6% | -$15.34M-25.5% | ||
| $321.38K+232% | $96.94K+188% | -$110.57K+35.2% | -$170.66K+34.9% | -$262.05K-184% | ||
| $269.93K+104% | -$6.13M+3.0% | -$6.31M+0.7% | -$6.35M+1.5% | -$6.45M-5,145% | ||
| -$28.29M+16.9% | -$34.04M+10.5% | -$38.02M-54.8% | -$24.55M-12.7% | -$21.79M-76.5% | ||
| -$28.32M+17.3% | -$34.26M+10.3% | -$38.2M-54.4% | -$24.74M-12.5% | -$21.98M-78.0% | ||
| —— | —— | -$26.21-30.7% | -$20.06-4.4% | -$19.22-54.4% | ||
| -$28.61M-2.3% | -$27.97M+11.8% | -$31.7M-74.2% | -$18.2M-18.6% | -$15.34M-25.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dogwood Therapeutics profitable?
- Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
- What is Dogwood Therapeutics's earnings per share?
- Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
- Where does Dogwood Therapeutics's income statement data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.